New trial
Phase 1 MOMA-341 study: Novel DNA damage response modulator in advanced solid tumors
- Trial ID
- NCT06974110 on ClinicalTrials.gov
- Cancer type
- Solid Tumor
- Stage of research
- First-in-human
- Location
- 4 Locations - 1 in the US (Dallas, TX), 3 in Australia
- Published in
- New in Oncology - Aug 15, 2025 (DOUBLE ISSUE)
This multi-center Phase 1 trial by MOMA Therapeutics evaluates the safety, tolerability, pharmacokinetics, and preliminary clinical activity of MOMA-341, a WRN helicase inhibitor, given as monotherapy or in combination with irinotecan—a topoisomerase I inhibitor—and immunotherapy in patients with advanced/metastatic MSI-H or dMMR solid tumors. The study uses dose escalation and optimization designs to determine dosing and assess early efficacy signals.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings